Neurological complications after intrathecal liposomal cytarabine application in patients after allogeneic haematopoietic stem cell transplantation
- 13 August 2008
- journal article
- research article
- Published by Springer Nature in Annals of Hematology
- Vol. 87 (12) , 1009-1012
Abstract
Liposomal cytarabine has been proven to be useful for the prevention and intrathecal treatment of neoplastic meningitis. It has no demonstrable myelosuppressive effects and may therefore be an attractive alternative for prophylaxis and treatment of the central nervous system (CNS) relapse after allogeneic haematopoietic stem cell transplantation (HSCT). The use of liposomal cytarabine had not been reported in HSCT recipients. We retrospectively reviewed the feasibility of liposomal cytarabine in the prophylaxis (n = 2) and treatment (n = 4) of neoplastic meningitis in a cohort of patients after allogeneic HSCT. This report focusses on neurological complications after intrathecal application of liposomal cytarabine. Mild headache was the most commonly reported adverse event. Two patients experienced sacral radiculopathy with irreversible cauda equina syndrome in one patient. Another patient progressed with pre-existing leukencephalopathy. Intrathecal liposomal cytarabine should be used very cautiously in allogeneic HSCT recipients with a history of CNS complications potentially involving cerebral-spinal fluid circulation, since significant neurotoxicity was observed in patients with extensive CNS-directed pre-treatment. The feasibility and safety of liposomal cytarabine in HSCT recipients has to be evaluated in a prospective study.Keywords
This publication has 7 references indexed in Scilit:
- Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemiaBlood, 2007
- Intrathecal liposomal cytarabine for prevention of meningeal disease in patients with acute lymphocytic leukemia and high-grade lymphomaLeukemia & Lymphoma, 2007
- Randomized Trial of a Slow-Release Versus a Standard Formulation of Cytarabine for the Intrathecal Treatment of Lymphomatous MeningitisJournal of Clinical Oncology, 1999
- Pharmacokinetics of Intralumbar DTC-101 for the Treatment of Leptomeningeal MetastasesArchives of Neurology, 1995
- Extended CSF cytarabine exposure following intrathecal administration of DTC 101.Journal of Clinical Oncology, 1993
- Central nervous system relapses after bone marrow transplantation for acute lymphoblastic leukemia in remissionCancer, 1989
- The risks of central nervous system relapse and leukoencephalopathy in patients receiving marrow transplants for acute leukemiaBlood, 1986